Maihub announced on September 15 that it has acquired Vuno’s AI-based bone age assessment solution, Vuno Med-BoneAge, for approximately $1.95 million. Approved by the Ministry of Food and Drug Safety in 2018, the product will be integrated into Maihub’s AI platform MaiLink and rebranded as mai:BoneAge for clinical use.

mai:BoneAge analyzes hand and wrist X-rays to assess growth plate development, supporting physicians in diagnosing pediatric endocrine disorders such as precocious puberty and growth hormone deficiency. Parents will also be able to access their children’s growth reports through a mobile app.

Until now, Maihub’s AI offerings have focused mainly on adult diseases, including breast cancer (Lunit), ophthalmic conditions (Mediwhale), osteoporosis (Promedius), degenerative diseases (Neurophet), and health screening (Talos). The acquisition marks its first step into pediatric healthcare, extending its coverage across all age groups.

A Maihub representative stated, “We are preparing pediatric packages, including conditions such as scoliosis and fractures. Specific indications are still under discussion.” The company aims to deliver tailored hospital solutions addressing unmet needs in pediatric diagnostics, an area where symptom reporting and traditional methods often fall short.

Meanwhile, Vuno said it will focus on expanding its biosignal-based portfolio, including a cardiac arrest prediction solution, while strengthening its global presence following the transfer of its bone age product.